XNAS · Healthcare · Biotechnology
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.40 | -0.50 | -25.00% | $0 | ❌ Miss | +0.00% | -8.79% | — |
| 2026-03-30 | Q4 2025 | -0.43 | -0.37 | +13.95% | $0 | ✅ Beat | +0.48% | +7.74% | +8.55% |
| 2025-11-13 |
| Q3 2025 |
| -0.46 |
| -0.40 |
| +13.04% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.49 | -0.47 | +4.08% | $0 | ✅ Beat | +0.86% | -11.89% | -14.52% |
| 2025-03-24 | Q4 2024 | -0.43 | -0.52 | -20.93% | $0 | ❌ Miss | +1.14% | -16.29% | -17.71% |
| 2024-03-27 | Q4 2023 | -1.82 | -0.50 | +72.53% | $0 | ✅ Beat | — | — | — |
| 2023-05-11 | Q1 2023 | -0.54 | -0.46 | +14.81% | $0 | ✅ Beat | +0.39% | +16.36% | +22.53% |
Showing last 7 quarters.